- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.06. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.05. | Acrivon Therapeutics GAAP EPS of -$0.51 beats by $0.10 | 3 | Seeking Alpha | ||
| 15.05. | Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock | 2 | Investing.com | ||
| 14.05. | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 14.05. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 548 | GlobeNewswire (Europe) | Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of... ► Artikel lesen | |
| 05.05. | Piper Sandler sets $6 target for Acrivon stock, rates it Overweight | 1 | Investing.com | ||
| 25.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 | 2 | GlobeNewswire (USA) | ||
| 07.04. | Acrivon appoints new chief medical officer to advance cancer trials | 1 | Investing.com | ||
| ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.04. | Acrivon ernennt neuen medizinischen Leiter zur Förderung von Krebsstudien | 2 | Investing.com Deutsch | ||
| 07.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer | 114 | GlobeNewswire (Europe) | Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of... ► Artikel lesen | |
| 07.04. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.03. | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.03. | H.C. Wainwright maintains Acrivon stock Buy rating, $19 target | 2 | Investing.com | ||
| 28.03. | Acrivon Therapeutics reports Q4 results | 6 | Seeking Alpha | ||
| 27.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results | 156 | GlobeNewswire (Europe) | Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive... ► Artikel lesen | |
| 27.03. | Acrivon Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright | 7 | Investing.com | ||
| 26.03. | Cantor Fitzgerald maintains Overweight on Acrivon stock | 3 | Investing.com | ||
| 26.03. | Acrivon stops developing Lilly castoff for ovarian and bladder cancers to switch focus to endometrial | 8 | FierceBiotech | ||
| 26.03. | JMP maintains Acrivon stock with $17 target following update | 3 | Investing.com |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,30 | -0,67 % | BioNTech-Konkurrent Moderna: Aktie mit Kurssprung - was ist da los? | Die Aktie von Moderna hat am Dienstag einen kräftigen Kurssprung hinlegen können. Das Papier ging als Top-Gewinner des Tages im S&P 500 vor Intel und Albemarle aus dem Handel. Moderna notiert nun so... ► Artikel lesen | |
| CUREVAC | 4,688 | +0,39 % | CureVac Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| AMGEN | 252,35 | -0,14 % | Amgen: Vom Biotech-Innovator zur Pharma-Größe | Im Laufe der Jahre hat sich Amgen von einem klassischen Biotechnologieunternehmen mit hohem Innovationsrisiko zu einem gereiften, cashflow-starken Unternehmen entwickelt. Die Geschäftsstruktur ähnelt... ► Artikel lesen | |
| NOVAVAX | 5,850 | -0,10 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| BIOGEN | 114,35 | -0,44 % | Biogen Inc.: Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress | - Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 -
- These findings support... ► Artikel lesen | |
| MAINZ BIOMED | 1,890 | -5,50 % | BRISANTE Meldung setzt Mainz Biomed Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
| VIKING THERAPEUTICS | 26,585 | -0,11 % | Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results | ||
| INTELLIA THERAPEUTICS | 9,710 | -1,52 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| GENMAB | 184,30 | +0,30 % | UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT | ||
| BIOCRYST PHARMACEUTICALS | 7,550 | +0,67 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development | RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head... ► Artikel lesen | |
| TEMPUS AI | 48,800 | 0,00 % | Cathie Wood's ARK buys Tempus AI stock, sells Block and Roku | ||
| SAREPTA THERAPEUTICS | 15,525 | -0,16 % | JPMorgan senkt Kursziel für Sarepta Therapeutics auf 28 US-Dollar | ||
| CARDIOL THERAPEUTICS | 1,120 | +0,36 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
| EXELIXIS | 38,870 | +1,25 % | Assessing Exelixis: Insights From 12 Financial Analysts | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,255 | -0,52 % | Here's Why You Should Add PacBio Stock to Your Portfolio Now |
Das Unternehmen ACRIVON THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,58 % bei einem Aktienkurs von 1,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACRIVON THERAPEUTICS INC finden Sie auf Wallstreet Online.